News

An audio recap of the top 5 stories in healthcare news from the week of 03/09-03/16

In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Anemia was linked to lower waist circumference, lower albumin levels, and treatment regimens in females, but not males.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

Liver transplants for alcohol-associated liver disease and alcohol-associated hepatitis have increased, but many centers lack necessary resources for care.

A new study highlights key risk factors of cold-induced anaphylaxis, including genetic markers and elevated IgE, expanding on findings from the COLD-CE study.

Food insecurity remained associated with incident CVD after adjustment for socioeconomic factors among participants in the 2000-2020 CARDIA study period.

In the final segment of this 6-part HCPLive RX Review, experts discuss resmetirom’s significance and what else gives them hope for the future of MASH care.

In the fifth segment of this 6-part HCPLive RX Review, experts discuss the evolving role of noninvasive testing in MASH care.

In the fourth segment of this 6-part HCPLive RX Review, experts discuss the continued importance of diet and exercise for managing MASH.

In the third segment of this 6-part HCPLive RX Review, experts discuss investigational therapies in the MASH pipeline and the use of combination therapy.

In the second segment of this 6-part HCPLive RX Review, experts discuss unmet needs in MASH care, even with resmetirom available as a treatment option.

In the opening segment of this 6-part HCPLive RX Review, experts reflect on resmetirom’s FDA approval for MASH and clinical challenges to implementing it.

Hoyte discussed findings from a post hoc analysis of the phase 3 NAVIGATOR study.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

A narrative review reports the connection between allergies and sleep and available treatment options for both conditions.

Chronic hypoparathyroidism requires holistic management addressing more than just calcium normalization to achieve optimal patient outcomes.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

The novel controlled metabolic accelerator significantly reduced fat-specific body weight but showed no improvements in exercise capacity over 19 weeks.

Carolyn Goh, MD, spoke in this AAD 2025 interview about her talk on guidance in addressing patients with hair disorders.

Among 162 patients in the study, 99% reported satisfaction of sublingual immunotherapy with real grocery store food.

Daily screen time exceeding 5 hours was associated with a greater risk of hepatic steatosis in adolescents, partially mediated by BMI.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

Chambliss also discussed other research she is working on looking to understand effects on children with asthma.

A cross-sectional cohort study identified several factors linked to eyewash use among individuals with allergic rhinitis.

Retransplantation in elderly patients was associated with a higher risk of DWFG but similar death-censored outcomes to primary transplantation.